Dentium CO., LTD (KRX:145720)
56,300
0.00 (0.00%)
Last updated: Sep 9, 2025, 9:58 AM KST
Dentium CO., LTD Revenue
Dentium CO., LTD had revenue of 82.25B KRW in the quarter ending June 30, 2025, a decrease of -26.34%. This brings the company's revenue in the last twelve months to 372.49B, down -9.68% year-over-year. In the year 2024, Dentium CO., LTD had annual revenue of 407.81B with 3.72% growth.
Revenue (ttm)
372.49B
Revenue Growth
-9.68%
P/S Ratio
1.30
Revenue / Employee
436.68M
Employees
853
Market Cap
485.53B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 407.81B | 14.62B | 3.72% |
Dec 31, 2023 | 393.19B | 37.32B | 10.49% |
Dec 31, 2022 | 355.87B | 64.34B | 22.07% |
Dec 31, 2021 | 291.53B | 61.78B | 26.89% |
Dec 31, 2020 | 229.75B | -22.84B | -9.04% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
PharmaResearch | 449.81B |
Peptron | 5.18B |
LigaChem Biosciences | 148.28B |